Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma

Blood Cancer J. 2021 Mar 19;11(3):63. doi: 10.1038/s41408-021-00454-y.

Authors

Kalyan Nadiminti^{1

2}, M Hasib Sidiqi¹, Kapil Meleveedu^{1

3}, Hassan B Alkhateeb¹, William J Hogan¹, Mark Litzow¹, Mrinal Patnaik¹, Shaji Kumar¹, Morie Gertz¹, Dong Chen⁴, Mithun Vinod Shah⁵

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Oncology, and Palliative Care, University of Wisconsin, Madison, WI, USA.
³ Division of Division of Bone Marrow Transplantation, Roger Williams Medical Center, Providence, RI, USA.
⁴ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
⁵ Division of Hematology, Mayo Clinic, Rochester, MN, USA. shah.mithun@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Aged
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Myeloid / etiology*
Leukemia, Myeloid / therapy
Male
Middle Aged
Multiple Myeloma / therapy*
Myelodysplastic Syndromes / etiology*
Myelodysplastic Syndromes / therapy
Survival Analysis
Transplantation, Autologous / adverse effects

Grants and funding

P50 CA186781/CA/NCI NIH HHS/United States